FMS Fresenius Medical Care AG

NYSE freseniusmedicalcare.com


$ 24.29 $ -2.06 (-7.82 %)    

Tuesday, 04-Nov-2025 15:59:55 EST
QQQ $ 615.11 $ -4.04 (-0.65 %)
DIA $ 470.25 $ 0.57 (0.12 %)
SPY $ 672.36 $ -0.79 (-0.12 %)
TLT $ 90.13 $ 0.15 (0.17 %)
GLD $ 362.19 $ -1.27 (-0.35 %)
$ 24.29
$ 23.84
$ 24.00 x 1
$ 26.00 x 2
$ 23.50 - $ 24.48
$ 19.34 - $ 29.71
1,936,034
na
7.13B
$ 0.49
$ 12.80
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fresenius-medical-care-q3-adj-eps-064-beats-059-estimate-sales-5712b-beat-5480b-estimate

Fresenius Medical Care (NYSE:FMS) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $...

 fresenius-medical-care-invests-312m-and-closes-share-purchase-agreement-with-all-non-physician-investors-in-interwell-health-expands-ownership-in-iwh

Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician invest...

 ubs-downgrades-fresenius-medical-care-to-sell

UBS analyst Graham Doyle downgrades Fresenius Medical Care (NYSE:FMS) from Neutral to Sell.

 amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales-momentum

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...

 fresenius-medical-care-confirms-its-outlook-for-fiscal-2025-and-expects-revenue-growth-to-be-positive-at-a-low-single-digit-percent-rate-compared-to-the-prior-year

Outlook 2025 confirmedFresenius Medical Care confirms its outlook for fiscal 2025 and expects revenue growth to be positive to ...

Core News & Articles

Azenta, Inc. (NASDAQ:AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Ca...

 fresenius-medical-cares-third-party-clinical-research-organization-frenova-collaborates-with-genewiz-to-advance-genomics-driven-precision-kidney-disease-care

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ b...

 fresenius-medical-care-partners-with-ccinshae-to-extend-highvolumehdf-access-in-mexico-through-pilot-program-for-uninsured-patients

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in MexicoIn Mexico, 240 CCINSHAE p...

 fresenius-medical-care-launches-value-based-care-segment-eyes-growth-through-innovation-efficiency

Fresenius Medical Care outlines new strategy with 5008X machine rollout in the U.S., launch of Value-Based Care segment, and co...

 fresenius-launches-fme-reignite-with-1b-annual-capex-plan-and-105b-cost-savings-target-by-2027

Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, today u...

 truist-securities-maintains-hold-on-fresenius-medical-care-raises-price-target-to-30

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:FMS) with a Hold and raises the price targe...

 fresenius-medical-care-expects-fy-2025-revenue-to-grow-by-a-low-single-digit-percentage

Fresenius Medical Care (NYSE:FMS) expects FY 2025 revenue to grow by a low single-digit percentage.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION